{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:26:19Z","timestamp":1755692779631},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,26]]},"DOI":"10.7759\/cureus.24488","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T07:43:16Z","timestamp":1650958996000},"source":"Crossref","is-referenced-by-count":2,"title":["Masked Primary Hyperparathyroidism by Empagliflozin Use"],"prefix":"10.7759","author":[{"given":"Mariam","family":"Awada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Melhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab M","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusef","family":"Hazimeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong MA","year":"2019","unstructured":"de Jong MA, Petrykiv SI, Laverman GD, et al.. Effects of dapagliflozin on circulating markers of phosphate homeostasis. Clin J Am Soc Nephrol. 2019, 14:66-73. 10.2215\/CJN.04530418","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2021.07.002","article-title":"Sodium-glucose co-transporter protein 2 inhibitors induced hypercalcemia: a case series and literature review","volume":"8","author":"El Masri D","year":"2022","unstructured":"El Masri D, Jamil Y, Eid Fares J. Sodium-glucose co-transporter protein 2 inhibitors induced hypercalcemia: a case series and literature review. AACE Clin Case Rep. 2022, 8:30-3. 10.1016\/j.aace.2021.07.002","journal-title":"AACE Clin Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo RA","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017, 13:11-26. 10.1038\/nrneph.2016.170","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10242","article-title":"Mineral and electrolyte disorders with SGLT2i therapy","volume":"3","author":"Cianciolo G","year":"2019","unstructured":"Cianciolo G, De Pascalis A, Capelli I, Gasperoni L, Di Lullo L, Bellasi A, La Manna G. Mineral and electrolyte disorders with SGLT2i therapy. JBMR Plus. 2019, 3:e10242. 10.1002\/jbm4.10242","journal-title":"JBMR Plus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-15-0042","article-title":"Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin","volume":"2015","author":"Kaur A","year":"2015","unstructured":"Kaur A, Winters SJ. Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin. Endocrinol Diabetes Metab Case Rep. 2015, 2015:150042. 10.1530\/EDM-15-0042","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2020-0113","article-title":"Hypercalcemic patient diagnosed with primary hyperparathyroidism after dapagliflozin treatment","volume":"6","author":"Akhanl\u0131 P","year":"2020","unstructured":"Akhanl\u0131 P, Hepsen S, Ucan B, Saylam G, Cakal E. Hypercalcemic patient diagnosed with primary hyperparathyroidism after dapagliflozin treatment. AACE Clin Case Rep. 2020, 6:e319-21. 10.4158\/ACCR-2020-0113","journal-title":"AACE Clin Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau JE","year":"2018","unstructured":"Blau JE, Bauman V, Conway EM, et al.. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 2018, 3:e99123. 10.1172\/jci.insight.99123","journal-title":"JCI Insight"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2017.08.003","article-title":"SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms","volume":"12","author":"Filippatos TD","year":"2018","unstructured":"Filippatos TD, Tsimihodimos V, Liamis G, Elisaf MS. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms. Diabetes Metab Syndr. 2018, 12:59-63. 10.1016\/j.dsx.2017.08.003","journal-title":"Diabetes Metab Syndr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang H","year":"2016","unstructured":"Tang H, Zhang X, Zhang J, Li Y, Del Gobbo LC, Zhai S, Song Y. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016, 59:2546-51. 10.1007\/s00125-016-4101-6","journal-title":"Diabetologia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/76945-masked-primary-hyperparathyroidism-by-empagliflozin-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:47Z","timestamp":1707507407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/76945-masked-primary-hyperparathyroidism-by-empagliflozin-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.24488","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}